Syndax Pharmaceuticals (SNDX) Misses Q2 EPS by 7c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.55), $0.07 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $73 million versus the consensus estimate of $79.8 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• BMO Capital Starts American Eagle Outfitters (AEO) at Market Perform
• Loop Capital Starts Affirm Holdings (AFRM) at Buy
• Galaxy Digital gets conditional classifications for 4.2 GW of Texas data centers